Indication:
For concomitant use with irradiation therapy in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. Tumor responses to hydroxyurea have been reported in melanoma, resistant chronic myelocytic leukemia and recurrent, metastatic or inoperable carcinoma of the ovary.
Dosage Forms:
Each Capsule contains Hydroxyurea USP—–500mg